GoodRx is a health information services business based in the US. GoodRx stocks (GDRX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $33.14 – an increase of 3.23% over the previous week. GoodRx employs 450 staff and has a trailing 12-month revenue of around $631.1 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$46.05|
|52-week range||$26.661 - $64.219|
|50-day moving average||$36.4971|
|200-day moving average||$36.5522|
|Wall St. target price||$42.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.815|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-09-15)||3.97%|
|1 month (2021-08-20)||37.01%|
|3 months (2021-06-22)||21.99%|
|6 months (2021-03-22)||22.41%|
Valuing GoodRx stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GoodRx's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GoodRx's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$79.1 million.
The EBITDA is a measure of a GoodRx's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$631.1 million|
|Gross profit TTM||USD$521.1 million|
|Return on assets TTM||-21.43%|
|Return on equity TTM||-118.05%|
|Market capitalisation||USD$18.6 billion|
TTM: trailing 12 months
There are currently 16.3 million GoodRx stocks held short by investors – that's known as GoodRx's "short interest". This figure is 14.6% down from 19.1 million last month.
There are a few different ways that this level of interest in shorting GoodRx stocks can be evaluated.
GoodRx's "short interest ratio" (SIR) is the quantity of GoodRx stocks currently shorted divided by the average quantity of GoodRx stocks traded daily (recently around 1.8 million). GoodRx's SIR currently stands at 8.99. In other words for every 100,000 GoodRx stocks traded daily on the market, roughly 8990 stocks are currently held short.
However GoodRx's short interest can also be evaluated against the total number of GoodRx stocks, or, against the total number of tradable GoodRx stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GoodRx's short interest could be expressed as 0.04% of the outstanding stocks (for every 100,000 GoodRx stocks in existence, roughly 40 stocks are currently held short) or 0.2566% of the tradable stocks (for every 100,000 tradable GoodRx stocks, roughly 257 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against GoodRx.
Find out more about how you can short GoodRx stock.
We're not expecting GoodRx to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.
Everything we know about the Imago BioSciences IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.Read more…
Everything we know about the Planet Labs IPO, plus information on how to buy in.
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
Everything we know about the Samsara IPO, plus information on how to buy in.
Everything we know about the Allbirds IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
Everything we know about the OnlyFans IPO, plus information on how to buy in.
Ever wondered how to buy shares in Vinco Ventures? We explain how and compare a range of providers that can give you access to many brands, including Vinco Ventures.
Steps to owning and managing Weber Inc. stocks, with 24-hour and historical pricing before you buy.
Everything we know about the Chobani IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.